Technology
Health
Biotechnology

TrovaGene

$4.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (9.23%) Today
+$0.12 (2.82%) After Hours

Why Robinhood?

You can buy or sell TrovaGene and other stocks, options, ETFs, and crypto commission-free!

About

TrovaGene, Inc. Common Stock, also called TrovaGene, is a clinical-stage, precision medicine oncology therapeutics company. Read More Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Employees
13
Headquarters
San Diego, California
Founded
1999
Market Cap
14.94M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
288.05K
High Today
$4.39
Low Today
$3.76
Open Price
$3.86
Volume
383.48K
52 Week High
$33.01
52 Week Low
$2.54

Collections

Technology
Health
Biotechnology
Medical
Therapy
US
North America

News

Guru FocusMar 13

Trovagene Receives Approximately $3.0 Million From Exercise of Warrants

SAN DIEGO, March 13, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that it has received approximately $3.0 million in proceeds from holders exercising common stock purchase warrants at an exercise price of $6.60 per share. The warrants were issued as part of the units sold in the Comp...

637
Guru FocusMar 12

Trovagene Regains Compliance with Nasdaq Listing Requirements

SAN DIEGO, March 12, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that it has regained compliance with Nasdaq listing requirements. In a letter dated March 11, 2019, Nasdaq informed the Company that it has regained compliance with the minimum bid price requirement. About Trovagene, ...

349
BenzingaMar 8

What's Behind TrovaGene's Volatile Ride? (NASDAQ:TROV)(NASDAQ:BPTH)

It's déjà vu for biotech investors, who witnessed a wild rally in Bio-Path Holdings Inc (NASDAQ: BPTH) this week. Shares of another thinly traded, nano-cap biotech are clocking double-digit gains for the second consecutive session. TrovaGene Inc (NASDAQ: TROV), which develops therapies targeting cell division to treat leukemia, lymphomas and solid tumors, gained more than 30 percent Thursday and was up about 70 percent midday Friday. The advance came in reaction to the company's fourth-quarter results, re...

1,221

Earnings

-$1.09
-$0.75
-$0.40
-$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$1.05 per share
Actual
-$1.09 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.